Table 5.

Adverse events of both groups.

Outcomes	Aspirin group (n=84)	Aspirin + rivaroxaban group (n=84)	P value
Allergy	0 (0.0%)	0 (0.0%)	1.000
Gastrointestinal bleeding	0 (0.0%)	1 (1.19%)	1.000
Intracranial hemorrhage	1 (1.19%)	1 (1.19%)	1.000
Urinary bleeding	0 (0.0%)0	0 (0.0%)	1.000
Meets the 3–5 levels of the BARC bleeding grading criteria	1 (1.19%)	1 (1.19%)	1.000
Meets the 1–2 levels of the BARC bleeding grading criteria	1 (1.19%)	2 (2.38%)	1.000
Total	2 (2.38%)	3 (3.57%)	0.650

BARC – bleeding academic research consortium.